Advertisement
Screener

AMARIN CORP PLC\UK (AMRN) Selling, General and Administrative Expense

2.8 / 5 stars · 68/120 Roast Me

AMARIN CORP PLC\UK Selling, General and Administrative Expense

AMARIN CORP PLC\UK (AMRN) reported Selling, General and Administrative Expense of $22.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-07-29

  • AMARIN CORP PLC\UK selling, general and administrative expense for the quarter ending 2026-06-30 was $22.19M, a 42.63% decline year-over-year.
  • AMARIN CORP PLC\UK selling, general and administrative expense for the quarter ending 2026-03-31 was $21.11M, a 42.27% decline year-over-year.
  • AMARIN CORP PLC\UK selling, general and administrative expense for the quarter ending 2025-12-31 was $20.06M, a 45.74% decline year-over-year.
  • AMARIN CORP PLC\UK selling, general and administrative expense for the quarter ending 2025-09-30 was $19.70M, a 46.63% decline year-over-year.
  • AMARIN CORP PLC\UK selling, general and administrative expense for fiscal 2025 was $115.00M, a 24.49% decline from fiscal 2024.
  • AMARIN CORP PLC\UK selling, general and administrative expense for fiscal 2024 was $152.31M, a 23.82% decline from fiscal 2023.
  • AMARIN CORP PLC\UK selling, general and administrative expense for fiscal 2023 was $199.94M, a 34.32% decline from fiscal 2022.
  • AMARIN CORP PLC\UK selling, general and administrative expense for fiscal 2022 was $304.42M, a 25.45% decline from fiscal 2021.
Period endSelling, General and Administrative Expense 3 monthSelling, General and Administrative Expense 6 monthSelling, General and Administrative Expense 9 monthSelling, General and Administrative Expense 12 month
2026-06-30$22.19M
10-Q · filed 2026-07-29
$43.30M
10-Q · filed 2026-07-29
$63.36M
derived: sum of 3 quarters · filed 2026-07-29
$83.06M
derived: sum of 4 quarters · filed 2026-07-29
2026-03-31$21.11M
10-Q · filed 2026-04-29
$41.17M
derived: sum of 2 quarters · filed 2026-04-29
$60.87M
derived: sum of 3 quarters · filed 2026-04-29
$99.54M
derived: sum of 4 quarters · filed 2026-07-29
2025-12-31$20.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$39.76M
derived: sum of 2 quarters · filed 2026-03-02
$78.43M
derived: sum of 3 quarters · filed 2026-07-29
$115.00M
10-K · filed 2026-03-02
2025-09-30$19.70M
10-Q · filed 2025-10-29
$58.37M
derived: sum of 2 quarters · filed 2026-07-29
$94.94M
10-Q · filed 2025-10-29
$131.91M
derived: sum of 4 quarters · filed 2026-07-29
2025-06-30$38.67M
10-Q · filed 2026-07-29
$75.25M
10-Q · filed 2026-07-29
$112.22M
derived: sum of 3 quarters · filed 2026-07-29
$149.12M
derived: sum of 4 quarters · filed 2026-07-29
2025-03-31$36.57M
10-Q · filed 2026-04-29
$73.54M
derived: sum of 2 quarters · filed 2026-04-29
$110.45M
derived: sum of 3 quarters · filed 2026-04-29
$148.99M
derived: sum of 4 quarters · filed 2026-04-29
2024-12-31$36.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$73.87M
derived: sum of 2 quarters · filed 2026-03-02
$112.42M
derived: sum of 3 quarters · filed 2026-03-02
$152.31M
10-K · filed 2026-03-02
2024-09-30$36.90M
10-Q · filed 2025-10-29
$75.45M
derived: sum of 2 quarters · filed 2025-10-29
$115.34M
10-Q · filed 2025-10-29
$159.28M
derived: sum of 4 quarters · filed 2026-03-02
2024-06-30$38.55M
10-Q · filed 2025-07-30
$78.44M
10-Q · filed 2025-07-30
$122.38M
derived: sum of 3 quarters · filed 2026-03-02
$167.83M
derived: sum of 4 quarters · filed 2026-03-02
2024-03-31$39.89M
10-Q · filed 2025-05-07
$83.83M
derived: sum of 2 quarters · filed 2026-03-02
$129.29M
derived: sum of 3 quarters · filed 2026-03-02
$180.24M
derived: sum of 4 quarters · filed 2026-03-02
2023-12-31$43.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$89.40M
derived: sum of 2 quarters · filed 2026-03-02
$140.35M
derived: sum of 3 quarters · filed 2026-03-02
$199.94M
10-K · filed 2026-03-02
2023-09-30$45.46M
10-Q · filed 2024-10-30
$96.41M
derived: sum of 2 quarters · filed 2024-10-30
$156.00M
10-Q · filed 2024-10-30
$224.13M
derived: sum of 4 quarters · filed 2025-03-12
2023-06-30$50.95M
10-Q · filed 2024-07-31
$110.54M
10-Q · filed 2024-07-31
$178.67M
derived: sum of 3 quarters · filed 2025-03-12
$237.42M
derived: sum of 4 quarters · filed 2025-03-12
2023-03-31$59.59M
10-Q · filed 2024-05-01
$127.72M
derived: sum of 2 quarters · filed 2025-03-12
$186.46M
derived: sum of 3 quarters · filed 2025-03-12
$273.36M
derived: sum of 4 quarters · filed 2025-03-12
2022-12-31$68.13M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12
$126.88M
derived: sum of 2 quarters · filed 2025-03-12
$213.77M
derived: sum of 3 quarters · filed 2025-03-12
$304.42M
10-K · filed 2025-03-12
2022-09-30$58.74M
10-Q · filed 2023-11-01
$145.64M
derived: sum of 2 quarters · filed 2023-11-01
$236.28M
10-Q · filed 2023-11-01
$328.65M
derived: sum of 4 quarters · filed 2024-02-29
2022-06-30$86.89M
10-Q · filed 2023-08-02
$177.54M
10-Q · filed 2023-08-02
$269.91M
derived: sum of 3 quarters · filed 2024-02-29
$372.87M
derived: sum of 4 quarters · filed 2024-02-29
2022-03-31$90.65M
10-Q · filed 2023-05-03
$183.01M
derived: sum of 2 quarters · filed 2024-02-29
$285.98M
derived: sum of 3 quarters · filed 2024-02-29
$393.18M
derived: sum of 4 quarters · filed 2024-02-29
2021-12-31$92.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$195.33M
derived: sum of 2 quarters · filed 2024-02-29
$302.54M
derived: sum of 3 quarters · filed 2024-02-29
$408.33M
10-K · filed 2024-02-29
2021-09-30$102.97M
10-Q · filed 2022-10-27
$210.17M
derived: sum of 2 quarters · filed 2022-10-27
$315.97M
10-Q · filed 2022-10-27
$432.78M
derived: sum of 4 quarters · filed 2023-03-01
2021-06-30$107.20M
10-Q · filed 2022-08-03
$213.00M
10-Q · filed 2022-08-03
$329.82M
derived: sum of 3 quarters · filed 2023-03-01
$449.98M
derived: sum of 4 quarters · filed 2023-03-01
2021-03-31$105.80M
10-Q · filed 2022-05-04
$222.61M
derived: sum of 2 quarters · filed 2023-03-01
$342.78M
derived: sum of 3 quarters · filed 2023-03-01
$435.17M
derived: sum of 4 quarters · filed 2023-03-01
2020-12-31$116.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$236.98M
derived: sum of 2 quarters · filed 2023-03-01
$329.38M
derived: sum of 3 quarters · filed 2023-03-01
$463.31M
10-K · filed 2023-03-01
2020-09-30$120.16M
10-Q · filed 2021-11-03
$212.56M
derived: sum of 2 quarters · filed 2021-11-03
$346.50M
10-Q · filed 2021-11-03
$442.52M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30$92.39M
10-Q · filed 2021-08-05
$226.33M
10-Q · filed 2021-08-05
$322.36M
derived: sum of 3 quarters · filed 2022-03-01
$404.92M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$133.94M
10-Q · filed 2021-04-29
$229.96M
derived: sum of 2 quarters · filed 2022-03-01
$312.52M
derived: sum of 3 quarters · filed 2022-03-01
$385.93M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31$96.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$178.58M
derived: sum of 2 quarters · filed 2022-03-01
$251.99M
derived: sum of 3 quarters · filed 2022-03-01
$323.62M
10-K · filed 2022-03-01
2019-09-30$82.56M
10-Q · filed 2020-11-05
$155.97M
derived: sum of 2 quarters · filed 2020-11-05
$227.60M
10-Q · filed 2020-11-05
$307.28M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30$73.41M
10-Q · filed 2020-08-04
$145.04M
10-Q · filed 2020-08-04
$224.72M
derived: sum of 3 quarters · filed 2021-02-25
$274.69M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31$71.63M
10-Q · filed 2020-04-30
$151.32M
derived: sum of 2 quarters · filed 2021-02-25
$201.28M
derived: sum of 3 quarters · filed 2021-02-25
$255.22M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31$79.69M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$129.65M
derived: sum of 2 quarters · filed 2021-02-25
$183.59M
derived: sum of 3 quarters · filed 2021-02-25
$227.00M
10-K · filed 2021-02-25
2018-09-30$49.96M
10-Q · filed 2019-11-05
$103.90M
derived: sum of 2 quarters · filed 2019-11-05
$147.31M
10-Q · filed 2019-11-05
$182.95M
derived: sum of 4 quarters · filed 2020-02-25
2018-06-30$53.94M
10-Q · filed 2019-07-31
$97.35M
10-Q · filed 2019-07-31
$132.99M
derived: sum of 3 quarters · filed 2020-02-25
$166.18M
derived: sum of 4 quarters · filed 2020-02-25
2018-03-31$43.41M
10-Q · filed 2019-05-01
$79.05M
derived: sum of 2 quarters · filed 2020-02-25
$112.24M
derived: sum of 3 quarters · filed 2020-02-25
$143.78M
derived: sum of 4 quarters · filed 2020-02-25
2017-12-31$35.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
$68.83M
derived: sum of 2 quarters · filed 2020-02-25
$100.38M
derived: sum of 3 quarters · filed 2020-02-25
$134.55M
10-K · filed 2020-02-25
2017-09-30$33.19M
10-Q · filed 2018-11-01
$64.74M
derived: sum of 2 quarters · filed 2018-11-01
$98.91M
10-Q · filed 2018-11-01
$130.13M
derived: sum of 4 quarters · filed 2019-02-27
2017-06-30$31.55M
10-Q · filed 2018-08-01
$65.72M
10-Q · filed 2018-08-01
$96.94M
derived: sum of 3 quarters · filed 2019-02-27
$123.00M
derived: sum of 4 quarters · filed 2019-02-27
2017-03-31$34.17M
10-Q · filed 2018-05-02
$65.40M
derived: sum of 2 quarters · filed 2019-02-27
$91.46M
derived: sum of 3 quarters · filed 2019-02-27
$117.52M
derived: sum of 4 quarters · filed 2019-02-27
2016-12-31$31.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27
$57.29M
derived: sum of 2 quarters · filed 2019-02-27
$83.35M
derived: sum of 3 quarters · filed 2019-02-27
$111.37M
10-K · filed 2019-02-27
2016-09-30$26.06M
10-Q · filed 2017-11-01
$52.13M
derived: sum of 2 quarters · filed 2017-11-01
$80.15M
10-Q · filed 2017-11-01
$103.67M
derived: sum of 4 quarters · filed 2018-02-27
2016-06-30$26.07M
10-Q · filed 2017-08-02
$54.09M
10-Q · filed 2017-08-02
$77.61M
derived: sum of 3 quarters · filed 2018-02-27
$104.33M
derived: sum of 4 quarters · filed 2018-02-27
2016-03-31$28.02M
10-Q · filed 2017-05-03
$51.54M
derived: sum of 2 quarters · filed 2018-02-27
$78.27M
derived: sum of 3 quarters · filed 2018-02-27
$104.32M
derived: sum of 4 quarters · filed 2018-02-27
2015-12-31$23.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
$50.25M
derived: sum of 2 quarters · filed 2018-02-27
$76.30M
derived: sum of 3 quarters · filed 2018-02-27
$101.04M
10-K · filed 2018-02-27
2015-09-30$26.73M
10-Q · filed 2016-11-03
$52.78M
derived: sum of 2 quarters · filed 2016-11-03
$77.52M
10-Q · filed 2016-11-03
$95.92M
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30$26.05M
10-Q · filed 2016-08-04
$50.80M
10-Q · filed 2016-08-04
$69.19M
derived: sum of 3 quarters · filed 2017-03-01
$88.46M
derived: sum of 4 quarters · filed 2017-03-01
2015-03-31$24.74M
10-Q · filed 2016-05-05
$43.14M
derived: sum of 2 quarters · filed 2017-03-01
$62.41M
derived: sum of 3 quarters · filed 2017-03-01
$83.50M
derived: sum of 4 quarters · filed 2017-03-01
2014-12-31$18.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
$37.67M
derived: sum of 2 quarters · filed 2017-03-01
$58.76M
derived: sum of 3 quarters · filed 2017-03-01
$79.35M
10-K · filed 2017-03-01
2014-09-30$19.27M
10-Q · filed 2015-11-04
$40.36M
derived: sum of 2 quarters · filed 2015-11-04
$60.95M
10-Q · filed 2015-11-04
$83.24M
derived: sum of 4 quarters · filed 2016-02-25
2014-06-30$21.09M
10-Q · filed 2015-08-06
$41.68M
10-Q · filed 2015-08-06
$63.97M
derived: sum of 3 quarters · filed 2016-02-25
$92.25M
derived: sum of 4 quarters · filed 2016-02-25
2014-03-31$20.59M
10-Q · filed 2015-05-08
$42.88M
derived: sum of 2 quarters · filed 2016-02-25
$71.15M
derived: sum of 3 quarters · filed 2016-02-25
$105.11M
derived: sum of 4 quarters · filed 2016-02-25
2013-12-31$22.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25
$50.57M
derived: sum of 2 quarters · filed 2016-02-25
$84.53M
derived: sum of 3 quarters · filed 2016-02-25
$123.80M
10-K · filed 2016-02-25
2013-09-30$28.27M
10-Q · filed 2014-11-06
$62.23M
derived: sum of 2 quarters · filed 2014-11-06
$101.50M
10-Q · filed 2014-11-06
$118.24M
derived: sum of 4 quarters · filed 2015-03-03
2013-06-30$33.96M
10-Q · filed 2014-08-07
$73.23M
10-Q · filed 2014-08-07
$89.96M
derived: sum of 3 quarters · filed 2015-03-03
$103.36M
derived: sum of 4 quarters · filed 2015-03-03
2013-03-31$39.27M
10-Q · filed 2014-05-09
$56.00M
derived: sum of 2 quarters · filed 2015-03-03
$69.40M
derived: sum of 3 quarters · filed 2015-03-03
$83.03M
derived: sum of 4 quarters · filed 2015-03-03
2012-12-31$16.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03
$30.13M
derived: sum of 2 quarters · filed 2015-03-03
$43.77M
derived: sum of 3 quarters · filed 2015-03-03
$57.79M
10-K · filed 2015-03-03
2012-09-30$13.40M
10-Q · filed 2013-11-07
$27.03M
derived: sum of 2 quarters · filed 2013-11-07
$41.06M
10-Q · filed 2013-11-07
$47.43M
derived: sum of 4 quarters · filed 2014-02-27
2012-06-30$13.63M
10-Q · filed 2013-08-08
$27.66M
10-Q · filed 2013-08-08
$34.04M
derived: sum of 3 quarters · filed 2014-02-27
$37.47M
derived: sum of 4 quarters · filed 2014-02-27
2012-03-31$14.03M
10-Q · filed 2013-05-09
$20.40M
derived: sum of 2 quarters · filed 2014-02-27
$23.83M
derived: sum of 3 quarters · filed 2014-02-27
$33.86M
derived: sum of 4 quarters · filed 2014-02-27
2011-12-31$6.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27
$9.81M
derived: sum of 2 quarters · filed 2014-02-27
$19.83M
derived: sum of 3 quarters · filed 2014-02-27
$22.56M
10-K · filed 2014-02-27
2011-09-30$3.43M
10-Q · filed 2012-11-08
$13.46M
derived: sum of 2 quarters · filed 2012-11-08
$16.18M
10-Q · filed 2012-11-08
2011-06-30$10.03M
10-Q · filed 2012-08-08
$12.75M
10-Q · filed 2012-08-08
2011-03-31$2.73M
10-Q · filed 2012-05-08
2010-09-30$2.13M
10-Q · filed 2011-11-08
$4.95M
derived: sum of 2 quarters · filed 2011-11-08
$7.21M
10-Q · filed 2011-11-08
2010-06-30$2.82M
10-Q · filed 2011-08-09
$5.07M
10-Q · filed 2011-08-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
ProPhase Labs, Inc. (PRPH)United States$0.006B-0.06
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
Pulmatrix, Inc. (PULM)United States$0.006B
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59
Ernexa Therapeutics Inc. (ERNA)United States$0.006B